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Abstract—Objective: The aim of this study is to develop a
smartphone-based high-frequency remote monitoring platform,
assess its feasibility for remote monitoring of symptoms in
Parkinsons disease, and demonstrate the value of data collected
using the platform by detecting dopaminergic medication re-
sponse.
Methods: We have developed HopkinsPD, a novel smartphone-
based monitoring platform, which measures symptoms actively
(i.e. data are collected when a suite of tests is initiated by
the individual at specific times during the day), and passively
(i.e. data are collected continuously in the background). After
data collection, we extract features to assess measures of five
key behaviors related to PD symptoms – voice, balance, gait,
dexterity, and reaction time. A random forest classifier is used
to discriminate measurements taken after a dose of medication
(treatment) versus before the medication dose (baseline).
Results: A worldwide study for remote PD monitoring was es-
tablished using HopkinsPD in July, 2014. This study used entirely
remote, online recruitment and installation, demonstrating highly
cost-effective scalability. In six months, 226 individuals (121
PD and 105 controls) contributed over 46,000 hours of passive
monitoring data and approximately 8,000 instances of structured
tests of voice, balance, gait, reaction, and dexterity. To the best
of our knowledge, this is the first study to have collected data at
such a scale for remote PD monitoring. Moreover, we demonstrate
the initial ability to discriminate treatment from baseline with
71.0(±0.4)% accuracy, which suggests medication response can
be monitored remotely via smartphone-based measures.
Index Terms—Parkinson’s disease, smartphone, remote moni-
toring, medication response detection.
I. INTRODUCTION
Parkinson disease (PD) is a progressive neurodegenera-
tive disease associated with substantial morbidity, increased
mortality, and particularly high economic burden [1]. The
prevalence of PD is increasing with as many as one million
Americans and an estimated seven to ten million people
worldwide living with PD [2]. Direct and indirect costs of
Parkinson’s are estimated to be nearly $25 billion annually in
the United States alone, and are expected to grow significantly
as the number of affected individuals increases [2].
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Currently, individuals living with PD have access to care
or participate in research primarily during in-person clinic
or research visits, which take place at most once every few
months. More frequent clinic visits are limited by travel dis-
tance, increasing disability, and uneven distribution of doctors
[3]. During clinic visits, clinicians assess current disease status
and adjust medication for their patients based on response and
side effects. However, a key challenge for PD treatment is that
PD progression varies among individuals [4]. Furthermore,
individuals may exhibit large variations [5]. More specifi-
cally, symptoms can fluctuate substantially over the medium
term, and the progression is not smooth for everyone [6].
Accordingly, it is difficult for clinicians to provide optimal
treatment for their patients based on these periodic “snapshots”
of the disease progression. Therefore, assessments based on
clinic visits alone are insufficient, and high frequency remote
monitoring is needed to improve the quantity and quality of
care for PD. For example, real-time, objective monitoring of
daily fluctuations in symptoms can enable timely assessments
of disease and response to treatment. These data can enable
more subtle adjustments of medications or other therapies for
PD and assessment of the efficacy of novel interventions.
Existing studies have required the use of specialized
and expensive medical devices such as wearable accelerom-
eters and gyroscopes, EEG and passive infrared sen-
sors [7][8][9][10][11][12][13]. Many of these studies have
also only reported data collected in the laboratory setting
[7][8][9][12][13], which does not faithfully represent the pat-
terns of variability that individuals with PD may experience at
home. In addition, the majority of past studies have focused
on monitoring only one aspect of PD such as dyskinesia [9],
gait [10][14][15][12][16], voice [17], postural sway [14], and
resting tremor [18][13]. However, PD is a multi-faceted dis-
ease with many varied symptoms. Thus, a multi-dimensional
approach is needed to continuously monitor all PD symptoms
at home.
Mobile phone based tracking and measurement tools offer a
promising new avenue for monitoring progressive conditions
outside the clinic. The smartphone is becoming one of the
most basic necessities. From a recent survey of 170,000
adult Internet users across 32 markets, 80% now own a
smartphone [19]. Moreover, without the need for expensive
specialized medical hardware, new software tools can be easily
downloaded and installed on an individual’s smartphone for
in-home monitoring.
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2Therefore, we hypothesize that a smartphone based platform
can be used to objectively and remotely measure aspects
related to PD (e.g., voice, balance, dexterity, gait, and reaction
time) and activities of daily living. To validate this hypothesis,
we have 1) developed HopkinsPD, a unified PD-specific
remote monitoring platform that incorporates both active and
passive tests to provide high frequency monitoring of symp-
toms and activities of daily living related to PD, 2) tested
the feasibility of an entirely remote, online recruitment and
installation process that enables large-scale, low-cost clinical
studies, and c) demonstrated that a machine learning approach
using the active tests can detect medication response with
71.0(±0.4)% accuracy.
II. BACKGROUND
The most widely-studied and understood symptoms in PD
pertain to impairments in the motor subsystem of the central
nervous system, including tremor at rest, bradykinesia, rigidity,
and postural instability. Other non-motor aspects of the dis-
ease include depression, anxiety, autonomic dysfunction, and
dementia, which are common and significantly affect health-
related quality of life of both individuals with PD and their
caregivers [1].
The Unified Parkinson’s Disease Rating Scale (UPDRS) is
the most widely used tool for assessing symptoms and clinical
status over time in PD [1]. The latest revision, MDS-UPDRS
[20], consists of assessments for 1) Non-motor Aspects of
Experiences of Daily Living (nM-EDL), 2) Motor Aspects of
Experiences of Daily Living (M-EDL), 3) Motor examination,
and 4) Motor complications. Currently, UPDRS assessments
are obtained subjectively by movement disorder specialists
[21].
The rapid rise of wearable consumer devices and smart-
phone technologies and the need for high frequency mon-
itoring of PD symptoms have led to a proliferation of re-
mote monitoring studies in PD. However, existing studies
suffer from the following shortcomings. First, the majority
of them rely on specialized medical hardware. For example,
studies have used wearable accelerometers and gyroscopes
[7][8][9][16][22], EEG [11][13], treadmill and video camera
[12], or passive infrared sensors [10]. Often these studies
require many sensors to be mounted at various positions on
the body [7][8][9]. Additionally, these commercial medical
devices are extremely expensive (often >$3,000 per device
excluding software) in comparison to the essential embedded
sensing hardware (e.g. MEMS accelerometer, ∼$5) and re-
quire the use of proprietary analysis algorithms whose internal
operation is not available to scientific scrutiny and independent
replication. These requirements significantly limit the use of
this technology in the home and community setting, and
for large-scale studies of PD symptoms. Secondly, existing
studies have typically focused on monitoring only one or two
aspects (e.g., dyskinesia [9], gait [10][14][15][12][16], voice
[17], postural sway [14], tremor [18][13][22], and bradykinesia
[22]) of PD. Since in PD no single symptom gives a full picture
of an individual’s disease state, a multi-dimensional approach
is needed to monitor PD comprehensively. Finally, previous
studies [7][8][9][12][13][16][22] have primarily reported data
from monitoring individuals with PD in the clinical laboratory
setting, which are therefore geographically and temporally
restricted. To the best of our knowledge, our study is the
first to collect high frequency PD-specific data objectively and
remotely, on such a large, worldwide scale.
Currently, there is no cure for Parkinson’s disease, but
treatment can help to control the symptoms. For instance, an-
tiparkinsonian medicines, like levodopa, can help control mo-
tor symptoms by increasing dopamine in brain. For individuals
with PD who have good medication response, the symptoms
of PD can be substantially controlled. By contrast, those in the
advanced stages of PD may suffer periods of “wearing off”,
i.e. the medication ceases to have any effect, and instead may
develop troublesome side effects such as levodopa-induced
dyskinesias and problems with impulse control. Since medica-
tion response and side effects vary by individual substantially,
a personalized medication regime is crucial to maintain quality
of life. However, it is difficult for clinicians to determine the
optimal regime based on brief moments of observation during
clinic visits. Monitoring medication response remotely and
objectively is one crucial idea for producing individually op-
timized PD medication regimes. Previous studies[16][22][23]
have attempted to monitor medication response remotely and
objectively, but are limited in terms of trial size and duration.
Weiss et al. [16] discovered that gait features improved sig-
nificantly when the medication effect peaked in a study on
22 PD participants in clinic by using a triaxial accelerometer
on their lower back. Mera et al. [22] deployed a finger-worn
motion sensor to 10 PD participants at home for six days. They
showed that rest and postural tremor and the average speed
and amplitude of hand movements were improved during
controlled tasks, and also highlighted the differences in motor
response to medication among individuals. Griffiths et al. [23]
used a wrist-worn motion sensor to continuously monitor 34
PD participants for 10 days. They showed the severity of
bradykinesia and dyskinesia before and after the change in
medication. Compared with these studies, our platform does
not require specialized medical hardware. Furthermore, our
platform allows cost-effective scaling in terms of numbers
of participants and study duration (e.g. monitoring more
than 200 participants continuously over six months); while
previous studies have only been feasible for very small datasets
(less than 34 participants) with short duration (less than ten
days). More importantly, previous studies have only explored
symptom-related features (e.g. amplitude of gait, speed of hand
movement) and response to medications. However, they do not
explore the discrimination of medication response.
III. METHODS
A. HopkinsPD Platform: Architecture and Monitoring Tests
Implemented
HopkinsPD allows the monitoring of PD symptoms re-
motely by using an application installed on the users’ own
smartphone. The most significant benefit of this mobile-based
approach is high accessibility. In particular, it is inexpensive
as no additional purchase is needed for smartphone owners
3TABLE I: Description of active tests in HopkinsPD
Test Description provided to participants Relevant PD Related MDS-UPDRS
symptoms III Motor exam
Voice Place the phone to your ear as if making a normal phone call, take a
deep breath, and say “aaah” for as long and as steadily as you can.
Dysphonia 3.1 Speech
Balance Stand up straight unaided and place the phone in your pocket for 30 Postural instability 3.12 Postural stability
seconds. 3.13 Posture
Gait Stand up and place the phone in your pocket. When the buzzer vibrates Bradykinesia 3.8 Leg agility
walk forward for 20 yards; then turn around and walk back. Freezing of gait 3.10 Gait
3.11 Freezing of gait
Dexterity Place the phone on a surface such as a desk or table. Tap the buttons Bradykinesia 3.4 Finger tapping
alternately with the index and middle finger of one hand, keeping a Reduced dexterity 3.5 Hand movements
regular rhythm.
Reaction Keep the phone on a surface as before. Press and hold the on-screen
button (i.e., at the bottom of the screen) as soon as it appears; release
it as soon as it disappears.
Bradykinesia
Reduced dexterity
3.5 Hand movements
Rest Tremor* Sit upright, hold the phone in the hand most affected by your tremor,
and rest it lightly in your lap.
Resting tremor 3.17 Rest tremor ampli-
tude
Postural Tremor* Sit upright and hold the phone in the hand most affected by your
tremor outstretched straight in front of you.
Postural Tremor 3.15 Postural tremor of
the hands
* Tests have been implemented but not used in this study.
Fig. 1: A closed loop for PD monitoring and intervention
and smartphone-based tests can be conducted anywhere and
at any time. This enables assessments at high frequency and
large scale in terms of numbers of recruits. Furthermore, it
can serve as a potential platform for incorporating care, e.g.,
telemedicine [3]. Therefore, HopkinsPD can be seen as a
preliminary step towards enabling a complete, “closed-loop”
remote monitoring and remote intervention tool for PD (Figure
1).
HopkinsPD enables fully-automated capture, compression,
encryption, and upload to secure server storage by both ac-
tively interacting with smartphone users and passively sensing
their daily activities (Figure 2). The core of the HopkinsPD
mobile application is a set of tests to monitor and assess symp-
toms appearing on the UPDRS scale through smartphones,
which consists of:
1) Active tests, tests that are initiated and self-administered
by the participants at various times during the day: these
tests are designed to measure several aspects of motor
function such as gait, voice, dexterity, reaction time, and
postural instability (balance), using built-in smartphone
sensors (See more details in Table I, and visual depiction
in Figure 10).
2) Passive tests, running continuously and unobtrusively
in the background, are designed to measure aspects of
daily living: these use the sensors such as accelerometer,
gyroscope, magnetic field strength, GPS location, WiFi
parameters, and phone usage logs to measure movement
(e.g. whether the individual is experiencing frozen gait
or dyskinesia), as well as location and social behavior
(e.g. whether they are primarily home-bound or have an
active lifestyle). Passive monitoring provides a way to
be monitored objectively without interrupting routine ac-
tivities. The successful monitoring of these daily details
may allow comprehensive insight into the behavior and
lifestyles of individuals living with PD, which have not
been fully investigated in previous studies.
3) Self-reported evaluation of their overall health, mood,
and well-being: the significant advantage of such
mobile-based questionnaires is that they can be com-
pleted outside the clinic. For example, considering that
about half to two-thirds of people with PD report that
they have memory problems [24], an on-demand survey
system which can probe such problems may be much
more accurate and effective than the current approach,
in which questionnaires can only be completed during
clinic visits thereby relying on the memory of individ-
uals to accurately report their own symptoms over the
last few months.
In addition to data collection, HopkinsPD provides HIPAA-
compliant data streaming to a secure server and web-based
analysis and visualization of the resulting data. Additional
specifics of the HopkinsPD system are summarized in the
Supplemental Section.
B. Study Enrollment
A feasibility study using HopkinsPD was launched in the
summer of 2014 to track and quantify characteristics of PD
on a worldwide scale [25]. In this study, participants were
4Fig. 2: HopkinsPD Architecture. See the Supplemental Section for more details on the system.
identified and recruited using an email database from the
Parkinsons Voice Initiative, online media, and patient registries
such as the Michael J. Fox Foundations Fox Trial Finder.
They were required to understand English and own an Android
smartphone with Internet access (e.g. WiFi). After enrollment,
participants received a confirmation email with an installation
URL to click, which automatically installed the application
directly onto their smartphone.
During the study, participants were asked to conduct active
tests and passive monitoring daily (self-report surveys were not
included in this study). Each time an individual initiated the
active tests within the HopkinsPD application, the application
required the user to perform five active tests measuring voice,
balance, gait, dexterity, and reaction time sequentially. We
refer to these five tests taken by the individual during a single
session as an instance of active tests. The participants were
asked to perform two instances of these active tests each day:
the first one in the morning just before taking medications,
and the second approximately one hour after the first. For
healthy controls, they were asked to perform the first in the
morning and the second one hour later. The characteristics
of participants and collected data are summarized in Section
IV-A.
C. Medication Response Detection by Using Active Tests
1) Feature Extraction: here, we focus on analyzing the
active test data leaving the analysis of passive monitoring
data for future work. Table II provides an exhaustive list
of the features extracted from the five types of active tests,
along with a brief description of each feature. Acceleration
features were based on definitions used in previous studies
[26][27][28]. Acceleration features were computed from the
tri-axial acceleration time series (x, y, and z-axis), as well
as the spherical transformation of the tri-axial acceleration
time series (i.e., radial distance, polar angle, and azimuth
angle). We apply the acceleration features in Table II for
these six axes respectively. As the acceleration time series
were sampled at irregular time intervals, we applied the Lomb-
Scargle periodogram to extract frequency-based features [29]
e.g. the dominant frequency component in Hz and its am-
plitude. All the acceleration features are used by both the
balance and gait tests. To extract the voice features, we first
divide the 20-second audio sample into 40 frames leading
to 0.5 second frame duration. Then, we tag each frame as
containing a ‘voiced’ signal if that frame has amplitude greater
than the first quartile of the amplitudes among all frames.
Then, for further analysis, we select the longest consecutive
run of voiced frames. The length of the largest consecutive
run of voiced frames is the “voice duration” feature. Other
features extracted from these voiced frames include dominant
frequency and amplitude (Table II). Dexterity features are
extracted from the stay duration, that is, the length of time
the finger stays touching the screen, and the move duration
which is the interval of time between a finger release and the
next finger press. The reaction features focus on the lag times
of finger reactions (i.e. the time intervals between the stimulus
appearing and the finger touch event).
2) Classification: here we investigate whether the active
tests can be used to detect dopaminergic medication response.
We use a random forest classifier to generate a mapping
from an active test instance to a discrimination of whether
the instance represents off treatment (tests performed before
medication) or on treatment (tests performed after medication
has been taken). The random forest classifier [32] is an
ensemble learning method for classification, regression and
other machine learning tasks. This method fits many decision
tree classifiers to randomly selected subsets of features and
averages the predictions from each of these classifiers. We
use a random forest classifier with 500 trees and the splitting
criterion is based on Gini impurity1.
Random forests can also be used to assess the relative
1Gini impurity is a standard measure used in classification and regression
trees (CART) [33] to indicate the diversity a set of training targets. It reaches
its minimum (zero) when all training cases in the node fall into a single target
class.
5TABLE II: Brief description of features extracted for active
tests
Feature Brief Description
Acceleration mean: Mean
Featuresa std: Standard deviation
Q1: 25th percentile
Q3: 75th percentile
IQR: Inter-quartile range (IQR) (Q3−Q1)
median: Median
mode: Mode (the most frequent value)
range: Data range (max - min)
skew: Skewness
kurt: Kurtosis
MSE: Mean squared energy
En: Entropy
MCR: Mean cross rate
DFC: Dominant frequency component
AMP: Amplitude of DFC
meanTKEO: Instantaneous changes in energy due to
body motionb
AR1: Autoregression coefficient at time lag 1
DFA: Detrended fluctuation analysis [30]
XCORR: Cross-correlation between two axes
MI: Mutural information between two axes
xEn: Cross-entropy between two axes
Voice Len: Voice duration in seconds
Features AMP: Voice amplitude
F0: Dominant voice frequency
AMP and F0 features include mean, standard devia-
tion, DFA, and the coefficients of polynomial curve
fitting with degree one and two respectively
Dexterity
Features
apply the same feature set (includes mean, standard
deviation, Q1, Q3, IQR, median, mode, range, skew,
kurt, MSE, En, meanTKEO, AR1, DFA) on two
groups of tapping intervals:
STAY: length of time finger stays touching the phone
screen
MOVE: time interval between release of touch to the
next touch event
Reaction
Features
apply the same feature set on the lags of finger
reactions (i.e. the time intervals between the stimulus
appearing and the finger touch event), including sum,
mean, standard deviation, Q1, Q3, IQR, median,
mode, range, skew, kurt, MSE, En, meanTKEO, DFA
a Acceleration features are used for both balance and gait tests
b TKEO stands for Teager-Kaiser energy operator [31]
importance of features in a classification problem. In our case,
the importance of features reflects how strongly predictive they
are of the effect of medication.
In addition, to compare against a “null” classifier, we use
a naı¨ve benchmark – the random classifier2. In theory this
random classifier should achieve exactly 50% performance
accuracy.
We use 10-fold cross validation (CV) with 100 repetitions
to estimate the out-of-sample generalization performance. For
each run of 10-fold CV, the original dataset is randomly
partitioned into 10 equal-sized subsets. Of the 10 subsets,
a single subset is retained as the validation subset (10% of
the instances), and the remaining nine subsets used as the
training data (90% of the instances). The CV process is then
repeated 10 times so that each of the 10 subsets is used
2A random classifier predicts the unknown active test group by guesses
based solely on the proportion of classes in the dataset, in this case, 50%
chance to be a baseline or a treatment instance.
TABLE III: Baseline characteristics
PD (N = 121) Control (N = 105)
Characteristic N (%) or mean (SD) N (%) or mean (SD)
Demographic information
Gender (% male) 71 (59) 56 (53)
Age (years) 57.6 (9.1) 45.5 (15.5)
Race (% white) 104 (86) 86 (82)
College graduate 100 (83) 76 (72)
Previous participant in PD
study? (% yes)
56 (46) 11 (10)
Technology information
Duration of smartphone own-
ership (>1 year)
111 (92) 97 (93)
Downloaded other apps previ-
ously? (% yes)
109 (90) 98 (94)
Search for health information
using phone? (% yes)
111 (92) 98 (94)
Clinical information
Care from PD specialist (%
yes)
68 (56) N/A
Years since symptoms began 5(19.8) N/A
Years since diagnosis 5(4.7) N/A
Years on medication(s) 5(4.7) N/A
exactly once as the validation set. We repeat this 10-fold
CV process 100 times after permuting the original instance
dataset uniformly at random. This provides a distribution of
classification accuracies which allows estimation of the mean
and standard deviation of the performance of the classifier
for unseen datasets, hence controlling for overfitting of the
classifier to the single available dataset. Classification results
are discussed in detail in Section IV-B.
IV. RESULTS
In this study our aim is to develop a smartphone-based
remote monitoring platform, to assess its feasibility for remote
monitoring of symptoms in Parkinson’s disease, and to demon-
strate the value of data collected by detecting dopaminergic
medication response. Here, we first illustrate the feasibility
of this entirely remote PD monitoring by summarizing the
characteristics of participants and the data collected in the
worldwide PD study. Then, we discuss the discriminative per-
formance on medication response detection and the ten most
predictive features indicated by the random forest classifier.
A. Data Collection Overview and Population Characteristics
Using the HopkinsPD platform, our study of remote PD
monitoring launched in 2014. To the best of our knowledge,
this is the first study to have collected continuous remote
monitoring data at such a large scale in terms of participant
size and participant duration. Any Android smartphone owner
can join and contribute at no cost. We elaborate several
advantages of our approach as follows:
For the first time, we have been able to run a PD-specific
research study with worldwide participation. Table III summa-
rizes the characteristics of participants living with PD versus
healthy controls. In our study, 226 individuals (121 PD and
105 controls) contributed data via HopkinsPD in the last half
of 2014. As shown in Figure 3, these participants come from
many of the world’s major population centers. Meanwhile, a
considerable number of healthy controls were also enrolled as
6Fig. 3: HopkinsPD enables worldwide remote monitoring.
Each red pin shows the location of a participant.
Fig. 4: Detailed characteristics of PD participants
participants. The demographics of PD participants and healthy
controls are similar, which is important because it will allow
us to discover PD-specific distinctions between them in fu-
ture. Moreover, the familiarity with smartphone usage among
the PD participants is comparable to the healthy controls,
which suggests that no special requirements are needed in
PD-specific remote monitoring studies. This indicates that
smartphone-based remote monitoring approaches which are
feasible for the healthy population would also be feasible for
PD research.
Moreover, with this number of PD participants we can gain
insight into the population variability of PD; Figure 4 depicts
the detailed characteristics of PD participants. The ages of
PD participants range from the 30s to 70s, including young
onset PD. Participants have varied education, employment and
marital status as well. These participants are also in different
stages of the disease, diagnosed from 1985 to 2014. Based
on this, they would be on various medication regimes. For
instance, more than ten types of anti-Parkinsonian drugs are
used among them; two-thirds of them need to take more than
one type of medication daily to manage their disease. This
variety among PD participants helps to ensure that the results
of any data analysis are as unbiased as possible.
Finally, we demonstrate high frequency data collection. As
of publication, over 46,000 hours of unstructured streaming
sensor data and 7,563 instances of structured tests of voice,
gait, posture, and dexterity were collected within 6 months.
This amount of data and the number of participants already far
exceeds previous smartphone-based studies [26] [28]. Figure
5 summarizes all the data collected from both active and
passive tests. Figures 5a and 5c show the number of active
test instances and the duration of passive monitoring by day of
week respectively, showing weekly data volume collection is
effectively uniform. Furthermore, Figures 5b and 5d illustrate
the number of active test instances and passive data collected
by hour of day, respectively. They show most active tests being
performed during the morning, and the passive monitoring
primarily covering the daytime, particularly from 08:00 to
18:00. As an illustration of high frequency data collection,
two timeline charts in Figure 6b show all active tests and
the periods of passive monitoring from a PD participant (ID:
roch0065): this participant started the data collection on July
16, 2014 and recorded 185 instances of active tests and 126
days of passive monitoring. Despite pauses in data collection,
which may be attributable to battery depletion, HopkinsPD
was still able to collect passive data during most daytime
hours.
Thus we demonstrate the feasibility of using a smartphone-
based remote monitoring platform to collect high frequency
data for large-scale PD research studies.
B. Results of Medication Response Detection
7,653 instances of active tests were collected from both
PD participants and healthy controls. To detect medication
response for PD participants, we used all the active test
instances from PD participants which can be paired into
baseline and treatment, giving 4,388 instances in total, to train
and evaluate the random forest classifier.
To quantify the performance of the random forest classifier
in detecting medication response, we calculate three com-
monly used performance measures:
• Sensitivity (true positive rate) – proportion of treatment
instances correctly identified.
• Specificity (true negative rate) – proportion of baseline
instances correctly identified.
• Accuracy – proportion of both treatment and baseline
instances correctly identified.
From Table IV we can see that the accuracy of the
random forest classifier is considerably higher than that of
random guessing, which indicates that medication response
7(a) Instances of active tests collected in each day of the week (b) Instances of active tests collected in each hour of the day
(c) Hours of passive monitoring in each day of the week (d) Hours of passive monitoring in each hour of the day
Fig. 5: Statistics of high frequency data collected from both active tests and passive monitoring
(a) One hundred eighty five instances of active tests collected (black
dots).
(b) One hundred twenty six days of passive monitoring (each blue
line segment represents one complete passive monitoring session)
Fig. 6: High frequency data collected for a PD participant (roch0065) within six months
is detectable by using active tests (p < 0.001, two-sided
Kolmogorov-Smirnov test). Based on these results, we can
reject the null hypothesis that random forests have no dis-
criminative power in detecting medication response.
The random forest classifier also indicates the importance
of features in creating the classification trees. The ten most
important features are described in Table V, and the density
plots of the feature differences between baseline and treatment
are depicted in Figure 7. Specifically, the following dexterity,
voice, and gait features are the most useful in predicting
response to dopaminergic medication:
• Improved tapping rhythm – The decrease of inter-quartile
range, standard deviation, mean squared energy and
the instantaneous energy changes of the finger press-
ing intervals suggests that finger tapping movements
become faster and more stable after taking medication.
This phenomenon indicates that medication relieves the
PD symptoms directly related to hand movements, e.g.
bradykinesia.
• Increased voice pitch – An increase in vocal pitch after
8TABLE IV: Performance measures of the methods used for
medication response detection
Method Sensitivity Specificity Accuracy
Random Forest 69.3± 0.5 72.7± 0.1 71.0± 0.4
Random Classifier 49.0± 0.1 50.9± 0.9 50.0± 0.6
Note: the results are reported in the form average ± standard
deviation in percentages (%).
Sensitivity = TP/(TP+TN)
Specificity = TN/(TN+FP)
Accuracy = (TP+TN)/(TP+TN+FP+FN)
Here TP, TN, FP, and FN stand for true positive, true negative, false
positive, and false negative, respectively.
medication suggests that medication may relieve specific
dysphonias such as monopitch.
• Improved gait – The increased inter-quartile range, stan-
dard deviation, and amplitude of the acceleration signals
during walking indicates that PD participants walk more
vigorously after taking medication. More specifically, the
changes of these features on axis y are more significant
than axes x and z. Since the y axis points to the ground
during the gait test, it indicates PD participants can lift
their feet higher off the floor after taking medication.
We also find that the accuracy of medication response de-
tection varies substantially with total daily levodopa equivalent
dose (LED) [34]. Here, the daily LED is computed via a
standardized formula from daily drug regimes, reported in
the pre-study survey [34]. Daily LED provides a useful tool
to express dose intensity of different anti-Parkinsonian drug
regimes on a single scale, and we assume that these regimes
do not change within six months. As shown in Figure 8, each
point indicates the average accuracy of medication response
detection for each individual3 versus the individual’s daily
LED. The dotted line is the quadratic polynomial regression
line. The medication response can be detected more accurately
with LED between 500 and 2000 mg than for low dose (less
than 500 mg) or high dose (larger than 2000 mg). This is
consistent with the fact that individuals with higher dosage
of medications are more likely to have (motor) fluctuations
in their disease and thus detectable changes in response to
treatment.
To further understand this, Figure 9 compares the different
medication responses between two individuals with different
LEDs. Participant roch0064, taking a medium LED (872 mg),
exhibits a distinct improvement on the ten features, while
the improvement is not obvious on roch0359, an individual
on low LED (120 mg). We speculate that for individuals
with low LED, the dose is too small to detect a clinically
important difference between baseline and treatment; however,
for individuals on the largest LED, usually with advanced
symptom severity, the medication “wears off” in between
doses, but high dosage also induces side effects such as
dyskinesias. Further investigation is required to validate these
conjectures.
3Here we only show the individuals with more than twenty active test
instances
TABLE V: The top ten features selected by the random forest
classifier
Feature ID Test Description
tap STAY IQR Dexterity inter-quartile range of finger
pressing intervals
gait y AMP Gait the amplitude of the dominant
frequency on axis y
voice F0 Voice the dominant voice frequency
tap STAY std Dexterity standard deviation of finger
pressing intervals
gait y std Gait standard deviation of axis y
gait r MSE Gait mean squared energy of the ra-
dial distances
gait r AMP Gait the amplitude of the dominant
frequency of the radial dis-
tances
tap STAY meanTKEO Dexterity mean TKEO of finger pressing
intervals
gait y IQR Gait inter-quartile range of axis y
tap STAY MSE Dexterity mean squared energy of finger
pressing intervals
V. DISCUSSION
In this study, we demonstrate that various objective mea-
surements of PD symptoms can be collected on a single
smartphone-based platform. Compared with consumer wear-
able devices and specialized medical equipment, smartphones
are far more pervasive (wearable devices are used by only less
than 10% of online adults, according to a recent survey [19]).
Moreover, our smartphone-based platform is a more flexible
and comprehensive toolkit compared to previous studies based
on a single wearable device. We believe that the smartphone is
the optimal “central hub” for remote monitoring of symptoms
in PD. Wearable devices like a wristband or a smart watch
could be useful accessories for certain important purposes,
e.g. sleep monitoring. It may also be that, in the future, a
smart watch with sufficient capability could entirely replace
the smartphone. Regardless, it is possible to integrate wearable
devices into HopkinsPD. Data streams from future wearable
devices would be another kind of passive test, and these data
can be synchronized to the phone via Bluetooth and securely
uploaded to the server using the existing framework. This
would allow raw sensor data collected from wearable devices
to be accessed by PD researchers.
Importantly, in our PD study, hundreds of individuals with
PD around the world, downloaded this PD-specific smartphone
application. This has provided tens of thousands of hours of
objective data on PD. We have shown that, these data coming
from individuals in their home environment, can be used to
detect medication response, namely whether the medication
improves dexterity, voice, and gait among as expected. We
have also observed that many participants do not improve
as much as others. The possible reasons include suboptimal
medication regimes or wearing-off and motor complications,
e.g. levodopa-induced dyskinesia. Further understanding and
verification of individualized daily motor fluctuations will be
key to closing the loop for integrated PD symptom monitoring
and intervention (Figure 1).
The current study is completely observational with no
interventional aspects. Future efforts could include the ability
9Fig. 7: Probabilty density of feature differences from treatment to baseline among all participants (red dashed lines at median
differences). The shift of the median differences from zero indicates the improvement on these features after taking medication.
Fig. 8: The relation between accuracy and daily LED
to provide near real-time feedback to participants on their
performance to enable them to have more control over their
condition. The functionality to complete more detailed surveys
such as the MDS-UPDRS, and the incorporation of additional
passive monitoring may also be valuable.
VI. CONCLUSION
Current clinical monitoring of PD is low-frequency and
based on periodic clinic visits. In contrast, we propose Hop-
kinsPD, a novel mobile smartphone-based platform to monitor
PD symptoms frequently and remotely. Our feasibility study
has shown that this approach enabled remote PD monitoring
on an unprecedented worldwide scale with very high frequency
data collection. By using the controlled tests carried out
using only the built-in smartphone sensors, initial experiments
using a set of features extracted from the sensor data and
random forest classification, is able to detect medication
response with 71.0(±0.4)% accuracy. Given the feasibility
of using smartphone-based monitoring platform to collect
high frequency clinical data and these preliminary results on
medication response detection, future studies could devise
novel models to track both the fluctuations in symptoms and
medication response over time in order to assess disease
progression, medication adherence, and, finally, help clinicians
make decisions on appropriate therapeutic interventions in-
formed by objective, near real-time, data.
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SUPPLEMENTAL SECTION: HOPKINSPD IMPLEMENTATION
To support all PD-specific tests on the smartphone applica-
tion (shown in Figure 10) and to facilitate study management
for PD researchers, we focus on two functional aspects of the
system:
A. Web-based Project Management and Visualization
The HopkinsPD web front-end is designed to make PD
studies manageable for researchers. It provides:
• Detailed project configuration. HopkinsPD allows re-
searchers to customize the application before launching.
In particular, researchers can configure which active tests
are enabled, which sensor data to collect during passive
monitoring, and which questionnaires to activate. To
bring this to light, they can turn on or turn off GPS
data collection and configure the sampling frequency,
e.g., once per minute or once per hour. The project
configuration is scripted using a simple XML file.
• Usage monitoring. A timeline view is provided for re-
searchers to track data collection progress remotely, as
(a) Primary interface (b) Self-report (c) Active tests
Fig. 10: HopkinsPD mobile application.
well as user participation in near real-time. An interactive
interface is provided in this view so that researchers can
specify a range of subjects and time. An example is
shown in Figure 11a.
• Multi-level visualization. To explore and visualize the
multidimensional data from both active and passive tests,
there are two different views provided: a) a test de-
tailed view displaying detailed sensor data plots with
zooming. For instance, researchers can visualize the three
dimensional acceleration sensor data collected from the
accelerometer when the subject is performing a gait test,
or play the sound recorded during the voice test; b) a
day view summarizing daily passive tests on a dashboard
consisting of various charts representing time-series of
movement sensor data (e.g., acceleration and compass),
location (GPS coordinates on a map), users’ interaction
with the phone (e.g. app usage and phone calls), and
resource consumption (e.g. battery level). This allows
researchers to monitor users’ daily activities. Examples
of data visualization are shown in Figure 11.
B. HIPAA-Compliant Security
To meet HIPAA requirements, the system must not broad-
cast identifiable patient data and must guarantee the authen-
ticity of the data it captures. HopkinsPD is designed to be
HIPAA-compliant to maintain the integrity of Protected Health
Information (PHI) for all participants, which is necessary in
that even though personal information such as names are
excluded from the platform, PHI could be inferred from data
collected from smartphones. Taking GPS as an example, co-
ordinates collected on the phone may expose the participants’
home or work address. Therefore, the backend of HopkinsPD
has implements the following:
• All data is immediately encrypted after collection on the
phone; secondly, all data uploaded to the server and all
results generated from that data are encrypted and stored
on a managed protected server with restricted access.
• Data transmission security. HopkinsPD implements a uni-
fied upload manager which uploads data collected via the
mobile frontend. This includes HTTPS-based encrypted
upload, error handling, and retry mechanisms.
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(a) Timeline: user monitoring
(b) An example of test view: voice view
(c) Part of the day view
Fig. 11: HopkinsPD web-based visualization.
• Access control and authentication. The account manage-
ment and access control are support authorized individual
data access in concurrent deployment settings. A Hopkin-
sPD account can be created by an administrator. Users
are authenticated based on their account credentials. The
access control in HopkinsPD is designed at a project level
so that for an account authorized to access Project A,
data collected from participants in Project A alone are
accessible to this account. This design isolates projects
from one another, thus allowing multiple studies to be
securely managed and deployed on the same backend.
The above functionalities greatly assist researchers in run-
ning remote PD studies and provide a secure data streaming
service to protect the data collection process.
